Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
Mukherjee S, Hurt CN, Gwynne S, Bateman A, Gollins S, Radhakrishna G, Hawkins M, Canham J, Lewis W, Grabsch HI, Sharma RA, Wade W, Maggs R, Tranter B, Roberts A, Sebag-Montefiore D, Maughan T, Griffiths G, Crosby T. Mukherjee S, et al. BMC Cancer. 2015 Feb 12;15:48. doi: 10.1186/s12885-015-1062-y. BMC Cancer. 2015. PMID: 25880814 Free PMC article. Clinical Trial.
ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.
Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, Chu KY, Durrant L, Abraham AG, Partridge M, Woodward M, O'Neill E, Maughan T, McKenna WG, Mukherjee S, Brunner TB. Wilson JM, et al. Radiother Oncol. 2016 May;119(2):306-11. doi: 10.1016/j.radonc.2016.03.021. Epub 2016 Apr 23. Radiother Oncol. 2016. PMID: 27117177 Free PMC article. Clinical Trial.
NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.
Mukherjee S, Hurt CN, Gwynne S, Sebag-Montefiore D, Radhakrishna G, Gollins S, Hawkins M, Grabsch HI, Jones G, Falk S, Sharma R, Bateman A, Roy R, Ray R, Canham J, Griffiths G, Maughan T, Crosby T. Mukherjee S, et al. Eur J Cancer. 2017 Mar;74:38-46. doi: 10.1016/j.ejca.2016.11.031. Epub 2017 Feb 8. Eur J Cancer. 2017. PMID: 28335886 Free PMC article. Clinical Trial.
Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).
Harrington K, Hall E, Hawkins M, Henry A, MacKay R, Maughan T, McDonald A, Nutting C, Oelfke U, Sebag-Montefiore D, Sharma RA, van Herk M, Faivre-Finn C; ART-NET Steering Committee. Harrington K, et al. Clin Oncol (R Coll Radiol). 2017 Nov;29(11):707-710. doi: 10.1016/j.clon.2017.07.016. Epub 2017 Aug 12. Clin Oncol (R Coll Radiol). 2017. PMID: 28807360 Free PMC article. No abstract available.
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
Strauss VY, Shaw R, Virdee PS, Hurt CN, Ward E, Tranter B, Patel N, Bridgewater J, Parsons P, Radhakrishna G, O'Neill E, Sebag-Montefiore D, Hawkins M, Corrie PG, Maughan T, Mukherjee S. Strauss VY, et al. BMC Cancer. 2019 Feb 4;19(1):121. doi: 10.1186/s12885-019-5307-z. BMC Cancer. 2019. PMID: 30717707 Free PMC article. Clinical Trial.
The polymorphic variant rs1800734 influences methylation acquisition and allele-specific TFAP4 binding in the MLH1 promoter leading to differential mRNA expression.
Thomas R, Trapani D, Goodyer-Sait L, Tomkova M, Fernandez-Rozadilla C, Sahnane N, Woolley C, Davis H, Chegwidden L, Kriaucionis S, Maughan T, Leedham S, Palles C, Furlan D, Tomlinson I, Lewis A. Thomas R, et al. Sci Rep. 2019 Sep 17;9(1):13463. doi: 10.1038/s41598-019-49952-x. Sci Rep. 2019. PMID: 31530880 Free PMC article.
238 results